SEC Form 4 · accession 0001290976-26-000002
Evommune, Inc. · EVMN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur S Kirsch
Director
Period of report
Jun 2, 2026
Accepted (ET)
Jun 3, 2026 · 8:03 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002044725
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F1 | $19.82 | Jun 2, 2026 | A | 15,673 | A | — | Jun 1, 2036 | Common Stock | 15,673 | 15,673 | D |
Explanation of responses
- F1The shares subject to the option award shall vest at the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.